Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.

Li YY.

World J Gastroenterol. 2012 Dec 7;18(45):6546-51. doi: 10.3748/wjg.v18.i45.6546. Review.

2.

PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.

Sookoian S, Pirola CJ.

World J Gastroenterol. 2012 Nov 14;18(42):6018-26. doi: 10.3748/wjg.v18.i42.6018.

3.

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.

Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN..

Hepatology. 2010 Sep;52(3):894-903. doi: 10.1002/hep.23759.

4.

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.

Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A.

BMC Med Genet. 2010 Dec 22;11:172. doi: 10.1186/1471-2350-11-172.

5.

Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people.

Zhou YJ, Li YY, Nie YQ, Yang H, Zhan Q, Huang J, Shi SL, Lai XB, Huang HL.

J Gastroenterol Hepatol. 2010 Apr;25(4):772-7. doi: 10.1111/j.1440-1746.2009.06144.x.

PMID:
20492333
6.

The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.

Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S.

BMC Gastroenterol. 2012 Aug 16;12:111.

7.

I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.

Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V.

Hepatology. 2010 Oct;52(4):1274-80. doi: 10.1002/hep.23823.

PMID:
20648474
8.

Potential epigenetic mechanism in non-alcoholic Fatty liver disease.

Sun C, Fan JG, Qiao L.

Int J Mol Sci. 2015 Mar 5;16(3):5161-79. doi: 10.3390/ijms16035161. Review.

9.

Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.

Domenici FA, Brochado MJ, Martinelli Ade L, Zucoloto S, da Cunha SF, Vannucchi H.

Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.

10.

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP.

Hepatology. 2010 Apr;51(4):1209-17. doi: 10.1002/hep.23622.

PMID:
20373368
11.

Association of adiponectin gene polymorphism with nonalcoholic fatty liver disease in Taiwanese patients with type 2 diabetes.

Hsieh CJ, Wang PW, Hu TH.

PLoS One. 2015 Jun 4;10(6):e0127521. doi: 10.1371/journal.pone.0127521. eCollection 2015.

12.

The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.

Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL.

Liver Int. 2011 Oct;31(9):1326-31. doi: 10.1111/j.1478-3231.2011.02526.x. Epub 2011 Apr 5.

PMID:
21745282
13.

Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.

Lin YC, Chang PF, Chang MH, Ni YH.

Am J Clin Nutr. 2014 Apr;99(4):869-74. doi: 10.3945/ajcn.113.079749. Epub 2014 Jan 29.

14.

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.

Dongiovanni P, Romeo S, Valenti L.

Biomed Res Int. 2015;2015:460190. doi: 10.1155/2015/460190. Epub 2015 Jul 27. Review.

15.

Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter.

Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ.

Hepatology. 2010 Dec;52(6):1992-2000. doi: 10.1002/hep.23927. Epub 2010 Oct 1.

PMID:
20890895
16.

Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.

Pirola CJ, Gianotti TF, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, Martino JS, Castaño GO, Sookoian S.

Gut. 2013 Sep;62(9):1356-63. doi: 10.1136/gutjnl-2012-302962. Epub 2012 Aug 9.

PMID:
22879518
17.

Genetic and epigenetic mechanisms of NASH.

Eslam M, George J.

Hepatol Int. 2016 May;10(3):394-406. doi: 10.1007/s12072-015-9689-y. Epub 2015 Dec 18. Review.

PMID:
26683320
18.

Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS; NASH CRN.; GIANT Consortium.; MAGIC Investigators., Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB; GOLD Consortium..

PLoS Genet. 2011 Mar;7(3):e1001324. doi: 10.1371/journal.pgen.1001324. Epub 2011 Mar 10.

19.

Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.

Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, Harris TB; Genetics of Obesity-Related Liver Disease (GOLD) Consortium., Nguyen T, Kamel IR, Bonekamp S, Eberhardt MS, Clark JM, Kao WH, Speliotes EK.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1183-1190.e2. doi: 10.1016/j.cgh.2013.02.011. Epub 2013 Feb 13.

20.

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.

Hepatology. 2016 Mar;63(3):787-98. doi: 10.1002/hep.28370. Epub 2016 Jan 14.

PMID:
26605757

Supplemental Content

Support Center